RESUMO
Background: The aim was to ascertain the 1-year clinical outcomes of 1,234 patients who underwent implantationsof sirolimus-eluting stents (SES) for acute myocardial infarction (MI) in the multinational e-SELECT registry.Methods: Fifteen thousand and one hundred and forty-seven patients treated with SES were entered in thee-SELECT registry, of whom 1,234 presented within <24 hours of onset of acute MI.Results: At 1 year, the rates of major adverse cardiac events (MACE) (5.5% vs. 4.8%; P = 0.28) were similarlylow in the acute and no acute MI groups. The rates of definite/probable stent thrombosis (ST) were higher inthe acute MI group (2.1%vs; 0.88%, P < 0.001). ST was a strong independent predictor of death at 1 year(HR 13.4; 95% CI 5.0, 36.0; P < 0.001) and MI (HR 58.9; 95% CI 26.9, 129.1; P < 0.001). Dual antiplatelettherapy (DAPT) compliance at 6 months was 96.0% in the acute MI versus 94.5% in the no acute MI group(P = 0.03).Conclusion: In selected patients presenting within <24 hours of acute MI onset and highly compliant with DAPT,SES implantation was associated with similar rates of MACE, though higher rates of ST, as compared to no acuteMI patients.Condensed abstractIn the e-SELECT registrywhich included 15,147 patients treated with sirolimus-eluting stent (SES), we ascertainedthe 1-year clinical outcomes of 1,234 patients who presented within <24 hours of acute MI onset. In acute MIpatients SES implantation was associated with similar rates of MACE, though higher rates of ST, as comparedto no acute MI patients (MACE: 5.5% vs. 4.8%; P = 0.28; ST: 2.1 vs. 0.88%, P < 0.001). (J Interven Cardiol2012;25:253261).